Valuation — not yet established
No valuation for Expansion Therapeutics is on record yet — no priced round, mark, or trade has surfaced in our sources. Total raised ($80.0M) and the funding record below are the closest available signals.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
See the evidence behind this price
- ·Post-money valuations for all 3 rounds
- ·Watchlist + deal alerts for Expansion Therapeutics
Create free account
No card required
Funding history
3 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Sep 2021 | Later Stage VC (Series B) | $80.0M | ▮ | ▮ |
| Dec 2017 | Early Stage VC | $25.3M | ▮ | ▮ |
| Nov 2016 | Debt | $5.0M | ▮ | ▮ |
How Expansion Therapeutics's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Expansion Therapeutics, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked
- How much has Expansion Therapeutics raised?
- Expansion Therapeutics has raised $80.0M in total funding across 3 recorded rounds.
- When did Expansion Therapeutics last raise?
- Expansion Therapeutics last raised in Sep 2021 (Later Stage VC (Series B)), raising $80.0M.